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ABSTRACT
BACKGROUND Limited data exist regarding transcatheter mitral valve replacement (TMVR) for patients with failed
mitral valve replacement and repair.
OBJECTIVES This study sought to evaluate the outcomes of TMVR in patients with failed mitral bioprosthetic valves
(valve-in-valve [ViV]) and annuloplasty rings (valve-in-ring [ViR]).
METHODS From the TMVR multicenter registry, procedural and clinical outcomes of mitral ViV and ViR were compared
according to Mitral Valve Academic Research Consortium criteria.
RESULTS A total of 248 patients with mean Society of Thoracic Surgeons score of 8.9  6.8% underwent TMVR.
Transseptal access and the balloon-expandable valve were used in 33.1% and 89.9%, respectively. Compared with
176 patients undergoing ViV, 72 patients undergoing ViR had lower left ventricular ejection fraction (45.6  17.4% vs.
55.3  11.1%; p < 0.001). Overall technical and device success rates were acceptable, at 92.3% and 85.5%, respectively.
However, compared with the ViV group, the ViR group had lower technical success (83.3% vs. 96.0%; p ¼ 0.001) due to
more frequent second valve implantation (11.1% vs. 2.8%; p ¼ 0.008), and lower device success (76.4% vs. 89.2%;
p ¼ 0.009) due to more frequent reintervention (16.7% vs. 7.4%; p ¼ 0.03). Mean mitral valve gradients were similar
between groups (6.4  2.3 mm Hg vs. 5.8  2.7 mm Hg; p ¼ 0.17), whereas the ViR group had more frequent post-
procedural mitral regurgitation moderate or higher (19.4% vs. 6.8%; p ¼ 0.003). Furthermore, the ViR group had more
frequent life-threatening bleeding (8.3% vs. 2.3%; p ¼ 0.03), acute kidney injury (11.1% vs. 4.0%; p ¼ 0.03), and
subsequent lower procedural success (58.3% vs. 79.5%; p ¼ 0.001). The 1-year all-cause mortality rate was signiﬁcantly
higher in the ViR group compared with the ViV group (28.7% vs. 12.6%; log-rank test, p ¼ 0.01). On multivariable
analysis, failed annuloplasty ring was independently associated with all-cause mortality (hazard ratio: 2.70; 95%
conﬁdence interval: 1.34 to 5.43; p ¼ 0.005).
CONCLUSIONS The TMVR procedure provided acceptable outcomes in high-risk patients with degenerated bio-
prostheses or failed annuloplasty rings, but mitral ViR was associated with higher rates of procedural complications and
mid-term mortality compared with mitral ViV. (J Am Coll Cardiol 2017;70:1121–31) © 2017 by the American College of
Cardiology Foundation.
Listen to this manuscript’s
audio summary by
JACC Editor-in-Chief
Dr. Valentin Fuster.
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I t is estimated that valvular heart diseaseaffects >100 million patients worldwide,which will increase further with the
aging population and a subsequent increase
in degenerative valve disease. Currently,
>40,000 mitral valve replacements are
performed annually in the United States,
and an analysis of the Society of Thoracic
Surgeons (STS) National Database indicated
a massive shift from mechanical to bio-
prosthetic valve replacements (1). Owing to
a considerable shift toward bioprosthesis
implantation, coupled with frequent repeat
operation after mitral valve replacement or
repair, it is expected that a growing number of
patients will present with degenerated bioprostheses
or failed annuloplasty rings (2,3). Although reopera-
tion is considered the standard of care for degener-
ated bioprostheses or failed annuloplasty rings,
these patients are frequently elderly, and repeat
cardiac surgery carries signiﬁcant morbidity and
mortality risks (4).
Since the ﬁrst successful transcatheter aortic valve
replacement was introduced by Alain Cribier in
2002 (5), this procedure has already been performed
in >250,000 patients worldwide, and it has become
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ABBR EV I A T I ON S
AND ACRONYMS
CI = conﬁdence interval
HR = hazard ratio
LVOT = left ventricular outﬂow
tract
MVARC = Mitral Valve
Academic Research Consortium
STS = Society of Thoracic
Surgeons
TMVR = transcatheter mitral
valve replacement
ViR = valve-in-ring
ViV = valve-in-valve
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the standard treatment in inoperable and high surgi-
cal risk patients (6–9). Furthermore, this technology
is being increasingly applied to a variety of pathol-
ogies such as degenerated bioprostheses (10).
Transcatheter mitral valve replacement (TMVR) for
degenerated mitral bioprostheses and failed annulo-
plasty rings has emerged as a less invasive alternative
to repeat cardiac surgery in selected patients deemed
at high surgical risk, but the experience of TMVR is
limited to small series (11–14). Although previous
studies showed the feasibility of TMVR for degen-
erated mitral bioprostheses and failed annuloplasty
rings, the diverse etiologies (stenosis, regurgitation,
or a combination of both) and device advancements
mandate comprehensive evaluation of clinical
outcomes of TMVR with a large cohort. Therefore, we
created an international multicenter registry of
patients undergoing TMVR.
METHODS
STUDY DESIGN AND PATIENT POPULATION. The
TMVR registry is an international, multicenter,
observational study that enrolled all consecutive
patients with mitral degenerated bioprostheses and
failed annuloplasty rings undergoing TMVR. The
registry was initiated in November 2015, and a total of
25 centers from Europe and North America partici-
pated in the registry. Patients were considered
candidates for the procedure if they had signiﬁcant
bioprosthetic mitral valve or annuloplasty ring
dysfunction (stenosis, regurgitation, or both), with
comorbid conditions that would preclude a repeat
sternotomy and valve replacement. We collected data
retrospectively for cases performed before initiation
and prospectively thereafter. This study was
approved by the institutional review board of each
institution, and all patients provided written
informed consent for TMVR and the use of anony-
mous clinical, procedural, and follow-up data for
research. For retrospective analysis of clinically
acquired and anonymized data, the institutional
review board of some institutions waived the need for
written patient informed consent.
STUDY DEVICES AND TMVR PROCEDURE. Patients
were selected for TMVR at the institutional level after
discussions by the multidisciplinary heart team.
Device size was selected based on a combination of the
manufacturer’s reported internal diameter and true
internal diameter as well as computed tomographic
and transesophageal echocardiographic measure-
ments (13,15,16). In addition, the valve-in-valve (ViV)
software application was used to ensure the proper
device size selection. The access site and type of
device were determined by themultidisciplinary heart
team. All TMVR procedures were conducted in accor-
dance with local guidelines using standard techniques
via transseptal, transapical, or transatrial access, and
the balloon-expandable transcatheter valves (Sapien,
Sapien XT, and Sapien 3 [Edwards Lifesciences, Irvine,
California], and Melody [Medtronic, Minneapolis,
Minnesota]) or other transcatheter valves (Lotus
[Boston Scientiﬁc, Natick, Massachusetts], and Direct
Flow [Direct Flow Medical, Santa Rosa, California])
were implanted (17–22).
ENDPOINTS AND DEFINITIONS. The primary end-
points of the present study were all-cause mortality
rates at 30 days and 1 year. Secondary endpoints were
technical, device, and procedural success and other
30-day major clinical endpoints deﬁned according to
the Mitral Valve Academic Research Consortium
(MVARC) criteria (23,24). Technical success was
determined at exit from the catheterization/operating
room and deﬁned as a procedure meeting all of the
following: absence of procedural mortality; success-
ful access, delivery, and retrieval of the device
delivery system; successful deployment and correct
positioning of the ﬁrst intended device; and freedom
from emergency surgery or reintervention related to
the device or access procedure. Device success was
assessed at 30 days and at all later post-procedural
intervals. This success was deﬁned as follows:
absence of procedural mortality or stroke; proper
placement and positioning of the device; freedom
from unplanned surgical or interventional procedures
related to the device or access procedure continued
intended safety and performance of the device,
including: 1) no evidence of structural or functional
failure; 2) no speciﬁc device-related technical failure
issues and complications; and 3) reduction of mitral
regurgitation to acceptable levels without signiﬁcant
mitral stenosis and with no greater than moderate
(2þ) paravalvular mitral regurgitation (and without
associated hemolysis). Although the original MVARC
criteria deﬁned signiﬁcant mitral stenosis as a
post-procedural transmitral gradient $5 mm Hg or an
effective oriﬁce area <1.5 cm2, a post-procedural
transmitral gradient $5 mm Hg was relatively
common in post-mitral valve replacement and repair
(25). Therefore, for the purpose of the present study,
we used modiﬁed criteria for signiﬁcant mitral
stenosis deﬁned as a transmitral gradient $10 mm Hg
and/or an effective oriﬁce area #1.0 cm2 according to
the American Society of Echocardiography guidelines
(26). Procedural success was determined at 30 days,
and it was deﬁned as a procedure that has achieved
device success without major clinical complications,
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including death, stroke, life-threatening/fatal
bleeding, major vascular complications, stage 2 or 3
acute kidney injury, severe congestive heart failure,
valve-related dysfunction, or other complications
requiring surgery or repeat intervention.
Other endpoints included procedure- and device-
related complications, as well as echocardiographic
assessment of the valve and cardiac function
immediately after the procedure and 30 days’ post-
procedurally. All echocardiographic, procedural, and
clinical data were assessed at each institution
according to MVARC criteria (23,24). The severity of
regurgitation was qualitatively assessed and graded
by using transthoracic echocardiography at each
institution according to established guidelines and
MVARC criteria (23,24,26).
DATA COLLECTION. Data collection included base-
line clinical, laboratory, echocardiographic, and
computed tomographic data, as well as procedural
data, antithrombotic treatment, and clinical follow-
up data, at pre-speciﬁed time points (1, 6, and
12 months and yearly thereafter). Follow-up was
obtained by clinical visits and/or through telephone
contacts. Referring cardiologists, general practi-
tioners, and patients were contacted whenever
necessary for further information. All data provided
by each institution were anonymized and centrally
collected, and all inconsistencies were resolved
directly with local investigators and on-site data
monitoring.
STATISTICAL ANALYSIS. Patients were stratiﬁed
according to whether they had TMVR for failed mitral
bioprosthetic valves or annuloplasty rings. Contin-
uous variables are presented as mean  SD and were
compared by using the Student t test or Mann-
Whitney U test. Categorical variables are presented
as counts or percentages and were compared by using
the chi-square or Fisher exact test. Cumulative rates
of death were calculated by using the Kaplan-Meier
survival analysis, and the log-rank test was used for
comparisons across the groups. Univariable Cox
regression models were used to evaluate potential
predictors of all-cause mortality at 1 year. Statistically
signiﬁcant variables with a p value <0.10 by
univariable analysis were included in the multivari-
able model. The ﬁnal model was determined by
backward elimination procedures with a threshold
p value <0.10. The proportional hazards assumption
was conﬁrmed by examination of log (–log [survival])
curves and by testing of partial (Schoenfeld)
residuals, and no relevant violations were found. The
estimated hazard ratio (HR) with 95% conﬁdence
interval (CI) was provided by the Cox model. All
statistical analyses were performed by using SPSS
version 24.0 (IBM SPSS Statistics [IBM Corporation,
Armonk, New York]). A 2-sided p value <0.05 was
considered to be statistically signiﬁcant.
RESULTS
BASELINE CHARACTERISTICS. A total of 248 pa-
tients with previous mitral valve surgery were treated
with TMVR across 25 participating centers between
February 2009 and February 2017. The baseline
characteristics of the study population are shown in
Table 1. Of the study population, 176 patients (71.0%)
had TMVR for degenerated mitral bioprosthetic
valves (ViV), and 72 patients (29.0%) had TMVR for
failed annuloplasty rings (valve-in-ring [ViR]). In the
overall cohort, the majority of patients were female
(56.9%), with a mean age of 72.5 years, and had a high
surgical risk with a mean STS score of 8.9  6.8% and
a logistic European System for Cardiac Operative Risk
Evaluation of 26.9  15.8%. Surgical risk scores were
similar between the ViV and ViR groups (STS score:
9.3  7.0% vs. 8.1  6.2%; p ¼ 0.24; logistic European
System for Cardiac Operative Risk Evaluation:
TABLE 1 Baseline Characteristics
Overall
(N ¼ 248)
ViV
(n ¼ 176)
ViR
(n ¼ 72) p Value
Age, yrs 72.5  12.1 72.9  12.8 71.4  10.2 0.36
Female 141 (56.9) 111 (63.1) 30 (41.7) 0.002
NYHA functional class III or IV 221 (89.1) 155 (88.1) 66 (91.7) 0.41
Logistic EuroSCORE, % 26.9  15.8 26.2  15.6 28.2  16.2 0.44
STS score, % 8.9  6.8 9.3  7.0 8.1  6.2 0.24
Diabetes mellitus 58 (23.4) 46 (26.1) 12 (16.7) 0.11
Creatinine, mg/dl 1.5  1.2 1.4  1.1 1.7  1.4 0.08
Hypertension 150 (60.5) 109 (61.9) 41 (56.9) 0.47
Peripheral vascular disease 18 (7.3) 11 (6.3) 7 (9.7) 0.34
Previous cerebrovascular accident 41 (16.5) 37 (21.0) 4 (5.6) 0.003
Chronic pulmonary disease 63 (25.4) 43 (24.4) 20 (27.8) 0.58
Coronary artery disease 93 (37.5) 57 (32.4) 36 (50.0) 0.009
Previous myocardial infarction 38 (15.3) 16 (9.1) 22 (30.6) <0.001
Previous PCI 37 (14.9) 21 (11.9) 16 (22.2) 0.04
Previous CABG 66 (26.6) 39 (22.2) 27 (37.5) 0.013
Echocardiographic ﬁndings
Mean gradient, mm Hg 11.0  6.1 12.4  5.8 6.9  5.1 <0.001
LVEF, % 52.5  13.9 55.3  11.1 45.6  17.4 <0.001
Mitral regurgitation
moderate or higher
190 (76.6) 125 (71.0) 65 (90.3) 0.001
Mechanism of failure
Regurgitation 120 (48.4) 64 (36.4) 56 (77.8) <0.001
Stenosis 66 (26.6) 63 (35.8) 3 (4.2) <0.001
Combined 62 (25.0) 49 (27.8) 13 (18.1) 0.11
Values are mean  SD or n (%).
CABG ¼ coronary artery bypass graft; EuroSCORE ¼ European System for Cardiac Operative Risk Evaluation;
LVEF ¼ left ventricular ejection fraction; NYHA ¼ New York Heart Association; PCI ¼ percutaneous coronary
intervention; STS ¼ Society of Thoracic Surgeons; ViR ¼ valve-in-ring; ViV ¼ valve-in-valve.
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26.2  15.6 vs. 28.2  16.2; p ¼ 0.44). The ViV group
was more likely to be female (63.1% vs. 41.7%;
p ¼ 0.002) and had more frequent previous cerebro-
vascular accidents (21.0% vs. 5.6%; p ¼ 0.003)
compared with the ViR group. However, the ViR
group had more extensive coronary artery disease
(50.0% vs. 32.4%; p ¼ 0.009) with more frequent
previous myocardial infarction (30.6% vs. 9.1%;
p < 0.001), previous percutaneous coronary inter-
vention (22.2% vs. 11.9%; p ¼ 0.04), previous coro-
nary artery bypass graft surgery (37.5% vs. 22.2%;
p ¼ 0.013), and lower left ventricular ejection fraction
(45.6  17.4% vs. 55.3  11.1%; p < 0.001). In terms of
failure mode, predominant mitral regurgitation was
more frequent in the ViR group compared with the
ViV group (77.8% vs. 36.4%; p < 0.001), whereas
mitral stenosis was more frequent in the ViV group
(35.8% vs. 4.2%; p < 0.001).
PROCEDURAL DATA. Patients treated with TMVR
had a variety of mitral bioprostheses and annulo-
plasty rings (Online Table 1). The median label size
and internal diameter of mitral bioprostheses were
29 mm and 27 mm, respectively. In terms of property
of annuloplasty rings, rigid, semi-rigid, and ﬂexible
rings were used in 14 patients (19.4%), 41 patients
(56.9%), and 9 patients (12.5%). Complete annulo-
plasty rings were used in 52 patients (72.2%), and the
median commissure-to-commissure distance of ring
was 29 mm.
The procedural data are summarized in Table 2.
With respect to access site, the majority of patients
were treated via transapical access (66.5%), and the
remaining patients were treated via transseptal
(33.1%) and transatrial (0.4%) access. Among patients
treated with transseptal access, an apical rail tech-
nique with wire externalization from venous access to
apical site was used in 4 patients (4.9%). The most
frequently used transcatheter valves were the
balloon-expandable valves (89.9%), followed by the
Lotus (5.6%) and the Direct Flow (4.4%). Balloon pre-
dilatation was performed in 8.5%, with no signiﬁcant
difference between the ViV and ViR groups, whereas
balloon post-dilatation was more frequently per-
formed in the ViR group compared with the ViV group
(12.5% vs. 4.0%; p ¼ 0.013).
PROCEDURAL AND CLINICAL OUTCOMES. The
procedural outcomes of the study population are
summarized in Table 3. Composite endpoints of
technical, device, and procedural success were
assessed according to MVARC criteria (Online
Table 2). In the overall group, procedure-related
death, conversion to conventional surgery, left
ventricular outﬂow tract (LVOT) obstruction, valve
embolization, and left ventricular perforation were
observed in 3 (1.2%), 5 (2.0%), 8 (3.2%), 4 (1.6%), and
1 patient (0.4%), respectively. Technical success was
achieved in the majority of patients (92.3%). How-
ever, the ViR group had a signiﬁcantly lower technical
success rate compared with the ViV group (83.3% vs.
TABLE 2 Procedural Data
Overall
(N ¼ 248)
ViV
(n ¼ 176)
ViR
(n ¼ 72) p Value
Access site
Transseptal access 82 (33.1) 62 (65.2) 20 (27.8) 0.26
Transapical access 165 (66.5) 113 (64.2) 52 (72.2) 0.23
Transatrial access 1 (0.4) 1 (0.6) 0 (0.0) >0.99
Device type
Balloon-expandable
valves
223 (89.9) 166 (94.3) 57 (79.2) <0.001
Sapien* 24 (9.7) 19 (10.8) 5 (6.9) 0.35
Sapien XT* 93 (37.5) 68 (38.6) 25 (34.7) 0.56
Sapien 3* 102 (41.1) 75 (42.6) 27 (37.5) 0.46
Melody† 4 (1.6) 4 (2.3) 0 (0.0) 0.33
Lotus‡ 14 (5.6) 8 (4.5) 6 (8.3) 0.24
Direct Flow§ 11 (4.4) 2 (1.1) 9 (12.5) <0.001
Balloon pre-dilatation 21 (8.5) 18 (10.2) 3 (4.2) 0.12
Balloon post-dilatation 16 (6.5) 7 (4.0) 9 (12.5) 0.013
Values are n (%). *Edwards Lifesciences, Irvine, California. †Medtronic, Minneap-
olis, Minnesota. ‡Boston Scientiﬁc, Natick, Massachusetts. §Direct Flow Medical,
Santa Rosa, California.
Abbreviations as in Table 1.
TABLE 3 Procedural Outcomes
Overall
(N ¼ 248)
ViV
(n ¼ 176)
ViR
(n ¼ 72) p Value
Procedure-related death 3 (1.2) 2 (1.1) 1 (1.4) >0.99
Conversion to conventional surgery 5 (2.0) 2 (1.1) 3 (4.2) 0.15
LVOT obstruction 8 (3.2) 4 (2.3) 4 (2.3) 0.18
Valve embolization 4 (1.6) 2 (1.1) 2 (2.8) 0.58
Need for second valve implantation 13 (5.1) 5 (2.8) 8 (11.1) 0.008
Left ventricular perforation 1 (0.4) 1 (0.6) 0 (0.0) >0.99
Technical success 229 (92.3) 169 (96.0) 60 (83.3) 0.001
Re-intervention 25 (10.1) 13 (7.4) 12 (16.7) 0.03
Paravalvular leak closure 9 (3.6) 4 (2.3) 5 (6.9) 0.07
Atrial septal defect closure 10 (4.0) 7 (4.0) 3 (4.2) 0.95
Surgical mitral valve replacement 4 (1.6) 2 (1.1) 2 (2.8) 0.58
Others 2 (0.8) 0 (0.0) 2 (2.8) 0.08
Echocardiographic ﬁndings
Mean gradient, mm Hg 6.0  2.6 5.8  2.7 6.4  2.3 0.17
Mean gradient $10 mm Hg 16 (6.5) 11 (6.3) 5 (6.9) 0.84
Mitral valve area, cm2 2.1  0.8 2.1  0.8 2.0  0.6 0.37
LVEF, % 50.3  13.6 52.8  12.0 44.1  15.4 <0.001
Mitral regurgitation moderate
or higher after procedure
26 (10.3) 12 (6.8) 14 (19.4) 0.003
Mitral regurgitation moderate
or higher at 30 days*
15 (6.5) 6 (3.6) 9 (13.6) 0.005
Device success (modiﬁed) 212 (85.5) 157 (89.2) 55 (76.4) 0.009
Values are n (%) or mean  SD. *Two-hundred thirty-two patients survived at 30 days were included.
LVOT ¼ left ventricular outﬂow tract; other abbreviations as in Table 1.
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96.0%; p ¼ 0.001) due to more frequent second valve
implantation (11.1% vs. 2.8%; p ¼ 0.008). Reinter-
vention was required in 25 patients (10.1%) and was
more frequent in the ViR group compared with the
ViV group (16.7% vs. 7.4%; p ¼ 0.03). Paravalvular
leak closure tended to be more frequent in the ViR
group compared with the ViV group (6.9% vs. 2.3%;
p ¼ 0.07), whereas there were no signiﬁcant differ-
ences between the ViV and ViR groups in atrial septal
defect closure (4.0% vs. 4.2%; p ¼ 0.95) and surgical
mitral replacement (1.1% vs. 2.8%; p ¼ 0.58).
With respect to echocardiographic ﬁndings, post-
procedural left ventricular ejection fraction was
lower in the ViR group compared with the ViV group
(44.1  15.4% vs. 52.8  12.0%; p < 0.001), whereas
there were no signiﬁcant differences between the
2 groups in mitral valve mean gradient (5.8 
2.7 mm Hg vs. 6.4  2.3 mm Hg; p ¼ 0.17) and mitral
valve area (2.1  0.8 cm2 vs. 2.0  0.6 cm2; p ¼ 0.37).
However, the incidence of moderate or greater mitral
regurgitation at post-procedure was signiﬁcantly
higher in the ViR group compared with the ViV group
(19.4% vs. 6.8%; p ¼ 0.003), which remained signiﬁ-
cantly higher at 30 days even after the closure of
paravalvular leakage (13.6% vs. 3.6%; p ¼ 0.005)
(Figure 1). Among 9 patients (4 patients in the ViV
group and 5 patients in the ViR group) who received
paravalvular leak closure after TMVR for the correc-
tion of signiﬁcant mitral regurgitation, 7 patients
(77.8%) showed improvement of mitral regurgitation
to less than moderate (ViV: 75.0%; ViR: 80.0%;
p > 0.99). In the ViR group, mitral regurgitation
moderate or higher at 30 days was more frequent in
patients with ﬂexible rings compared with those with
semi-rigid rings (44.4% vs. 10.8%; p ¼ 0.02) (Online
Figure 1). It is noteworthy that there was no patient
who had signiﬁcant mitral stenosis with a transmitral
mean gradient $10 mm Hg and mitral valve
area #1.0 cm2. Due to more frequent reintervention
and lower technical success rate, the device success
rate was signiﬁcantly lower in the ViR group compared
with the ViV group (76.4% vs. 89.2%; p ¼ 0.009).
Clinical outcomes are summarized in Table 4.
There were no signiﬁcant differences between the
ViV and ViR groups in 30-day all-cause mortality
(5.7% vs. 8.3%; p ¼ 0.44), stroke (2.3% vs. 0%;
p ¼ 0.33), major or extensive bleeding (6.3% vs. 4.2%;
p ¼ 0.52), or major vascular complication (1.7% vs.
FIGURE 1 Mitral Regurgitation
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Mitral regurgitation at the time of transcatheter mitral valve replacement procedure, immediately post-procedure, and after 30 days. The grade of mitral regurgitation
was divided into none to trace (0þ), mild (1þ), moderate (2þ), moderate to severe (3þ), and severe (4þ). ViR ¼ valve-in-ring; ViV ¼ valve-in-valve.
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1.4%; p > 0.99). However, the ViR group had more
frequent life-threatening or fatal bleeding (8.3% vs.
2.3%; p ¼ 0.03) and stage 2 or 3 acute kidney injury
(11.1% vs. 4.0%; p ¼ 0.03) compared with the ViV
group, which resulted in a signiﬁcantly lower proce-
dural success rate in the ViR group (58.3% vs. 79.5%;
p ¼ 0.001).
IMPACT OF ACCESS SITE AND LEARNING CURVE. With
stratiﬁcation according to whether patients were
treated via transseptal or transapical access, proce-
dural and clinical outcomes are shown in Online
Figure 2. There were no signiﬁcant differences
between transseptal and transapical access in
procedural-related death, conversion to surgery,
LVOT obstruction, second valve implantation, and
technical success. However, patients in the trans-
septal group required more frequent closure of an
iatrogenic atrial septal defect compared with the
transapical group (12.2% vs. 0.0%; p < 0.001), which
resulted in lower device success rate (78.0% vs.
89.1%; p ¼ 0.02). Nevertheless, there were no signif-
icant differences between the 2 groups in clinical
outcomes at 30 days and procedural success. Given
that the median number of TMVR procedures at each
institution was 8, patients were divided into the early
experience group (the ﬁrst 7 cases) and the late
experience group (the 8th case and thereafter). There
were no signiﬁcant differences between the early and
late experience groups in terms of procedural and
30-day clinical outcomes for the overall cohort as well
as the transseptal cohort (Online Figures 3 and 4).
MID-TERM MORTALITY. Over a median follow-up
period of 220 days (interquartile range, 40 to
560 days), 48 patients died in the overall cohort
(28 patients in the ViV group and 20 patients in the
ViR group). The cumulative event rate for all-cause
mortality at the 1-year follow-up was 16.9%, with
signiﬁcantly higher all-cause 1-year mortality in the
ViR group compared with the ViV group (28.7% vs.
12.6%; log-rank test, p ¼ 0.01) (Central Illustration).
There were no signiﬁcant differences between the
transseptal and transapical access groups in 1-year
all-cause mortality (16.2% vs. 17.4%; log-rank test,
p ¼ 0.74) (Figure 2). On univariable analysis, the fac-
tors associated with 1-year all-cause mortality were
age, predominant mitral regurgitation at baseline, left
ventricular ejection fraction, failed annuloplasty ring,
and moderate or greater post-procedural mitral
regurgitation. After adjustment with multivariable
analysis, age (HR: 1.04; 95% CI: 1.00 to 1.08; p ¼ 0.03)
and failed annuloplasty ring (HR: 2.70; 95% CI: 1.34
to 5.43; p ¼ 0.005) were independently associated
with 1-year all-cause mortality (Table 5).
ANTITHROMBOTIC THERAPY AND CLINICAL THROMBOSIS.
Information regarding anticoagulation and post-
procedural thrombosis was available in 236 patients
(95.2%: 166 patients in the ViV group and 70 patients
in the ViR group). Among them, 152 patients (64.4%)
received anticoagulation (warfarin or direct oral
anticoagulant agents) for at least 3 months after
TMVR, and 84 patients (35.6%) received antiplatelet
agents only after TMVR (Figure 3). Among patients
receiving only antiplatelet agents, 3 patients
presented with symptomatic mitral valve thrombosis
within 1 month after TMVR (3.6%), whereas no
patients had clinical mitral valve thrombosis when
receiving anticoagulant agents (p ¼ 0.04).
DISCUSSION
The present study is, to the best of our knowledge, the
ﬁrst large-scale study that evaluated the safety, efﬁ-
cacy, and clinical outcomes of TMVR in patients with
degenerated mitral bioprostheses and failed annulo-
plasty rings. The major ﬁndings of the present study
are as follows: 1) in the overall cohort, the procedural
and clinical outcomes of TMVR for patients with
degenerated mitral bioprostheses and failed annulo-
plasty rings were acceptable despite high surgical
risk with multiple comorbidities; 2) compared with
patients with degeneratedmitral bioprostheses, TMVR
for patients with failed annuloplasty rings was asso-
ciated with lower rates of technical, device, and pro-
cedural success; and 3) the cumulative event rates for
all-cause mortality after TMVR at the 1-year follow-
up were higher in patients with failed annuloplasty
rings compared with those with degenerated mitral
bioprostheses.
TABLE 4 Clinical Outcomes
Overall
(n ¼ 248)
ViV
(n ¼ 176)
ViR
(n ¼ 72) p Value
All-cause mortality at
30 days
16 (6.5) 10 (5.7) 6 (8.3) 0.44
Stroke 4 (1.6) 4 (2.3) 0 (0.0) 0.33
Bleeding
Major or extensive 14 (5.6) 11 (6.3) 3 (4.2) 0.52
Life-threatening or
fatal
10 (4.0) 4 (2.3) 6 (8.3) 0.03
Major vascular
complication
4 (1.6) 3 (1.7) 1 (1.4) >0.99
Acute kidney injury
(stage 2 or 3)
15 (6.0) 7 (4.0) 8 (11.1) 0.03
Procedure success 182 (73.4) 140 (79.5) 42 (58.3) 0.001
All-cause mortality
at 1 year*
33 (16.9) 18 (12.6) 15 (28.7) 0.01
Values are n (%). *Cumulative rates and p value were calculated using the Kaplan-
Meier survival analysis and log-rank test, respectively.
Abbreviations as in Table 1.
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Recently, several studies reported the acceptable
clinical outcomes of TMVR for patients with degen-
erated bioprosthesis or failed annuloplasty rings
(11,27–29). However, these studies were limited in
sample size, type of previous mitral valve surgery
(replacement or repair), and access site. A substan-
tial portion of patients required reoperation after
either mitral valve replacement or repair (30), but
reoperation after mitral valve surgery is associated
with increased perioperative mortality and
morbidity in elderly patients (4), which leads to a
large number of undertreated patients with degen-
erated mitral bioprostheses and dysfunctional
annuloplasty rings. Therefore, comprehensive
understanding of outcomes of TMVR for both
degenerated bioprosthesis and failed annuloplasty
ring is essential. Furthermore, advancements in
transcatheter valves with smaller proﬁles have
enabled easier transseptal access; this approach
needs further assessment of its efﬁcacy and safety
compared with the conventional transapical
approach.
In the present study, patients with degenerated
mitral bioprosthesis and failed annuloplasty rings
both exhibited high surgical risk, with mean STS
scores of 9.3% and 8.1%, respectively. However,
CENTRAL ILLUSTRATION Kaplan-Meier Curves for Mortality After Mitral Valve-in-Valve and Valve-in-Ring
Yoon, S.-H. et al. J Am Coll Cardiol. 2017;70(9):1121–31.
Procedural and post-procedural computed tomography images of mitral valve-in-valve and valve-in-ring are shown (upper panel). The cumulative all-cause mortality
rates of the overall cohort (purple line), patients undergoing mitral valve-in-valve (orange line), and valve-in-ring (blue line) are shown (lower panel).
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there were signiﬁcant differences in baseline charac-
teristics: female subjects and previous cerebrovascu-
lar accidents were more frequent in the ViV group;
and the ViR group had more frequent predominant
mitral regurgitation with extensive coronary artery
disease and lower left ventricular ejection fraction
compared with the ViV group, which may reﬂect the
recurrence and progression of ischemic mitral regur-
gitation after mitral valve repair with ring annulo-
plasty. In the present study, high technical and
device success rates of mitral ViV were observed in a
variety of types and sizes of mitral bioprostheses as
well as mode of failure. Although anatomical
challenges with the transseptal approach or more
invasive transapical approach are required in TMVR,
the accumulated experience and evidence from
“aortic” ViV may help to select appropriate device
size and accurate deployment of transcatheter valves.
However, compared with mitral ViV, mitral ViR was
associated with lower technical, device, and proced-
ure success.
The challenges of the mitral ViR procedure may be
attributable to several factors: 1) initially elliptical
annuloplasty rings need to become circular during the
TMVR procedure, but the various degrees of rigidity
of annuloplasty rings and the absence of deﬁnite
recommendations regarding the appropriate size and
type of transcatheter devices led to difﬁculties in
predicting the ring deformability and resulted in
more frequent mitral regurgitation; and 2) the
optimal implantation of a transcatheter valve is
limited due to the existence of native anterior mitral
leaﬂet and insufﬁcient ﬁxation with annuloplasty
rings, resulting in more frequent need for second
valve implantation or LVOT obstruction with too low
deployment in the left ventricular cavity.
The mitral ViV was initially performed via a
transseptal and transatrial approach by Webb et al.
(31), but difﬁculties in achieving a coaxial alignment
of the transcatheter valve and mitral bioprosthesis
has established the transapical approach as a more
feasible route thereafter (13). Nevertheless, the
present study showed that the procedural and clinical
outcomes of the transseptal approach were compa-
rable to those of the transapical approach, except for
the more frequent requirement of closure of an
iatrogenic atrial septal defect. The challenges in
achieving coaxiality and stabilization of a balloon-
expandable valve with transseptal access may be
overcome by the optimized transseptal puncture
guided by intraoperative transesophageal echocardi-
ography (16). Although the present study did not
show improved outcomes with increased experience,
the impact of a less invasive procedure on clinical
outcomes should be evaluated in a larger cohort with
longer term follow-up.
Mid- and long-term mortality may be affected by
procedural complications in combination with base-
line comorbidities and underlying mitral valve dis-
ease. The higher mid-term mortality of ViR compared
TABLE 5 Predictors of All-Cause Mortality
Univariable Model Multivariable Model
HR (95% CI) p Value HR (95% CI) p Value
Age, yrs 1.03 (0.99–1.07) 0.07 1.04 (1.00–1.08) 0.03
Female 0.84 (0.42–1.67) 0.62
NYHA functional class
III or IV
0.86 (0.30–2.46) 0.78
STS score, % 1.03 (0.99–1.07) 0.14
Creatinine, mg/dl 1.10 (0.88–1.37) 0.39
Peripheral vascular disease 0.74 (0.18–3.10) 0.68
Previous cerebrovascular accident 0.81 (0.31–2.11) 0.67
Chronic pulmonary disease 1.08 (0.50–2.33) 0.84
Previous CABG surgery 0.89 (0.40–1.97) 0.77
Predominant mitral regurgitation at
baseline
2.15 (1.04–4.44) 0.04
LVEF per increase of 10% 0.80 (0.63–1.01) 0.06
Transseptal access 0.88 (0.41–1.90) 0.75
Failed annuloplasty ring 2.39 (1.20–4.75) 0.01 2.70 (1.34–5.43) 0.005
Post-procedural mitral regurgitation
moderate or higher
2.32 (0.90–6.01) 0.08
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Table 1.
FIGURE 2 Kaplan-Meier Curves for Mortality After Transseptal and Transapical TMVR
0 90 180 270 360
17.4%
16.2%
165 97 90Transapical
No. at Risk
82 33 30Transseptal
Transapical Transseptal
Log-rank p = 0.74
Al
l-C
au
se
 M
or
ta
lit
y 
(%
)
Days
40
30
20
10
0
Cumulative all-cause mortality rates in patients undergoing transcatheter mitral
valve replacement (TMVR) via transseptal (orange line) and transapical (blue line) ac-
cess are shown.
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with ViV warrants careful selection of patients for a
ViR procedure. LVOT obstruction was a potentially
devastating complication, and its prediction still
poses a challenge (32,33). In addition, the need for
second valve implantation in the mitral position rai-
ses the concern for increase of transmitral pressure
gradient or risk of intra-atrial thrombosis (25,34).
Furthermore, the nature of the underlying mitral
valve disease could affect the long-term outcomes.
Nevertheless, given the early experience and lack of
knowledge and evidence in TMVR ﬁelds, further im-
provements in procedural and consequently better
clinical outcomes of TMVR are awaited in the future.
These improvements will be achieved through
comprehensive understanding of the TMVR proced-
ure, accumulation of experience and appropriate
technique for the successful procedure, establish-
ment of guidelines for size and type of transcatheter
valves, and technical device advancement.
The risk of thrombosis has been increasingly
recognized after transcatheter valve replacement in
the setting of ViV implantations (32), particularly in
the mitral position (33,34). According to the recently
updated 2014 American Heart Association/American
College of Cardiology guidelines, anticoagulation
therapy with warfarin is reasonable for the ﬁrst
3 months after surgical bioprosthetic mitral valve
replacement as well as transcatheter “aortic” valve
replacement (Class IIa) (35). However, limited data
exist regarding antithrombotic treatment for ViV
procedures. In the present study, the absence of
anticoagulation was associated with early mitral
valve thrombosis, which may be attributable to low
transvalvular pressure. The present results do not
allow for provision of recommendations on the
duration of anticoagulant treatment after TMVR.
Future studies are awaited to assess the optimal
duration of anticoagulation treatment after TMVR.
STUDY LIMITATIONS. First, this study had the
inherent limitations of an observational study
without center-independent adjunction of adverse
events and an independent core laboratory to assess
mitral regurgitation. In addition, the outcomes in this
study could differ from those in “real- world” practice
due to potential selection biases. Moreover, device
selection was not randomized but left at the opera-
tor’s discretion, and patient selection as well as
operator experience may have affected the observed
outcomes.
CONCLUSIONS
The TMVR procedure provided acceptable outcomes
in high-risk patients with degenerated bioprostheses
or failed annuloplasty rings, but mitral ViR was
associated with higher rates of procedural complica-
tions and mid-term mortality compared with
mitral ViV.
ADDRESS FOR CORRESPONDENCE: Dr. Raj R.
Makkar, Cedars-Sinai Heart Institute, 8700 Beverly
Boulevard, Los Angeles, California 90048. E-mail: raj.
makkar@cshs.org.
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: TMVR provided acceptable
outcomes in high-risk patients with degenerated bio-
prostheses or annuloplasty rings, but ViR procedures
were associated with higher rates of complications
and mid-term mortality than ViV replacement.
TRANSLATIONAL OUTLOOK: Future studies
should evaluate the long-term outcomes and optimal
antithrombotic treatment of patients undergoing
TMVR for degenerated bioprostheses or failed
annuloplasty rings.
FIGURE 3 Antithrombotic Treatment
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The rates of antithrombotic treatment for the ﬁrst 3 months
after transcatheter mitral valve replacement are shown.
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